Molecular genetic testing showed no mutation of BRAF V600E, which may be found up to 50% of gangliogliomas and pleomorphic xanthoastrocytomas [21], in either of our 2 cases or in 4 cases tested by Huse et al. Nevertheless, Huse et al. demonstrated a point mutation involving MEK 1 (MAP 2 K1) in 1 out of 8 tested cases. This evidence concerns the gene MAP2K1 and pleomorphic xanthoastrocytoma.